ArticleDrug delivery and translational research2026
Self-assembling RADA16-I peptide in situ hydrogel loaded with Celastrol boost immunogenic cell death in oral squamous cell carcinoma.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biomaterial-based Drug delivery strategies for head and neck cancer: Local delivery, combination therapy, and translational challenges.International journal of pharmaceutics: X · 2026Review
- The Antitumor Potential of Celastrol: Research Progress on Antitumor Mechanisms and Strategies for Toxicity Reduction with Efficacy Enhancement.Biomolecules · 2026Review
- Construction of a Three-Dimensional Culture Model of HSV-1 Based on the Nano-Self-Assembling Peptide RADA16-I and Preliminary Exploration of the Relationship Between HSV-1 and Autophagy.Microorganisms · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Oral squamous cell carcinoma (OSCC) is one of the most common malignant tumors of the head and neck and is characterized by high heterogeneity and high recurrence rates. In particular, the serious side effects of radiotherapy and chemotherapy are the main obstacles in OSCC treatment. It is worth noting that immune infiltration is associated with the occurrence of OSCC. However, the effective induction of a robust immune response remains challenging because of the limited responsiveness of most patients with oral cancer. Celastrol (CeT) has excellent therapeutic efficacy against cancers, but is poorly soluble in water. We used RADA16-I hydrogel loaded with CeT (RADA-CeT) to improve its solubility and stability. The results indicated that the complex formed by the interaction between RADA16-I and CeT exhibited better stability, smaller particle size, excellent dispersibility, and high elasticity. Particularly, RADA-CeT hydrogel was more effective in activating damage-associated molecular patterns, thereby evoking immunogenic cell death (ICD) in OSCC cells. In vivo experiments demonstrated that RADA-CeT hydrogel had a stronger promoting effect on the expressions of CD4, CD8, calreticulin (CRT), and high-mobility group box-1 (HMGB1). Thus, RADA-CeT exhibited excellent anti-tumor efficacy by amplifying ICD. In the present study, we developed a biocompatible drug delivery system for uncaging the power of CeT in OSCC immunotherapy.
Indexed as
Identifiers
40824412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.